Brain Imaging Study of F17464

Healthy Volunteers Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01689038
• Other study ID #: F17464 PO 1 02
• Status: Completed
• Phase: Phase 1
• First received: September 14, 2012
• Last updated: February 13, 2013
• Start date: November 2012
• Est. completion date: February 2013

Study information

• Verified date: February 2013
• Source: Pierre Fabre Medicament
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Assess the binding rate of F17464 to cerebral receptors in healthy volunteers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: February 2013
• Est. primary completion date: February 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Male healthy volunteers

Exclusion Criteria:

• Presence or positive history of severe medical illness or psychiatric conditions

Study Design

Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• F17464
Single dose

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Pierre Fabre Medicament

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Binding rate to cerebral receptors	by brain imaging	up to 29 hours	No